Physician profile
Bhadresh Patel
NPI 1003913252
$5,851.05
in general payments reported to CMS, 2019-2025
36 companies · $749 in 2025
The $749 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,623 · 2020: $548 · 2021: $1,138 · 2022: $676 · 2023: $599 · 2024: $518 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,383.03 | 2019-2025 | |
| Novo Nordisk INC | $636.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $499.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $487.28 | 2021-2025 | |
| Amgen INC. | $435.83 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $380.22 | 2019-2025 | Farxiga, Breztri |
| Amarin Pharma, INC. | $270.72 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.12 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $217.14 | 2020-2024 | |
| Astellas Pharma US INC | $190.29 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $176.14 | 2020-2023 | Mounjaro, Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $158.10 | 2019-2022 | |
| Abbott Laboratories | $99.47 | 2021-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $89.59 | 2021-2025 | Keveyis |
| Sanofi-Aventis U.S. LLC | $57.63 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $47.52 | 2020-2025 | Zoryve |
| Boston Scientific Corporation | $45.31 | 2023-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $40.67 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.83 | 2022 | |
| Merck Sharp & Dohme LLC | $39.48 | 2024-2025 | Verquvo, Capvaxive |
| Sunovion Pharmaceuticals INC. | $39.22 | 2021 | |
| Allergan, INC. | $31.04 | 2019-2020 | |
| Covidien Lp | $27.71 | 2019 | |
| Mannkind Corporation | $27.00 | 2019 | |
| Organogenesis INC. | $22.01 | 2021 | |
| Dexcom, INC. | $21.74 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $21.20 | 2021 | |
| Esperion Therapeutics, INC. | $20.75 | 2022 | |
| Nestle Healthcare Nutrition INC. | $19.44 | 2022 | |
| Mylan Specialty L.P. | $19.24 | 2021 | |
| Biogen, INC. | $15.79 | 2021 | |
| Sumitomo Pharma America, INC. | $15.32 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $14.91 | 2021 | |
| Radius Health, INC. | $14.28 | 2023 | Tymlos |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhadresh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.